Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Gilbert

Showing results (51-60 of 91) with videos related to

Pageof 10
Sort By:
Academic Medicine : Journal of the Association of American Medical Colleges|November 30, 2007
Creating an integrated clinical enterprise at the University of Kentucky: the emergence of UK HealthCareMichael Karpf, Jay Perman, Richard Lofgren, et al.
The Science of the Total Environment|September 2, 2024
Potential for large losses of carbon from non-native conifer plantations on deep peat over decadal timescalesThomas J Sloan, Joshua Ratcliffe, Russell Anderson, et al.
Journal of the Royal Society, Interface|June 29, 2021
Timing HIV infection with a simple and accurate population viral dynamics modelDaniel B Reeves, Morgane Rolland, Bethany L Dearlove, et al.
The Journal of Infectious Diseases|May 8, 2012
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)Ann Duerr, Yunda Huang, Susan Buchbinder, et al.
Bioorganic & Medicinal Chemistry Letters|March 24, 2010
Synthesis and bioluminescence-inducing properties of autoinducer (S)-4,5-dihydroxypentane-2,3-dione and its enantiomerManikandan Kadirvel, William T Stimpson, Souad Moumene-Afifi, et al.
Journal of Virology|July 30, 2005
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccinesJohn R Mascola, Patricia D'Souza, Peter Gilbert, et al.
Human Vaccines & Immunotherapeutics|March 10, 2015
Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infectionSandhya Vasan, Supachai Rerks-Ngarm, Peter Gilbert, et al.
The Journal of Infectious Diseases|December 4, 2012
Reply to Richie and VillasanteAnn Duerr, Yunda Huang, Susan Buchbinder, et al.
Science Translational Medicine|April 22, 2011
HIV-1 vaccines and adaptive trial designsLawrence Corey, Gary J Nabel, Carl Dieffenbach, et al.
Plos One|September 7, 2012
MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral loadHolly Janes, Nicole Frahm, Allan DeCamp, et al.
Pageof 10

Showing results (51-60 of 91) with videos related to

Sort By:
Pageof 10
Academic Medicine : Journal of the Association of American Medical Colleges|November 30, 2007
Creating an integrated clinical enterprise at the University of Kentucky: the emergence of UK HealthCareMichael Karpf, Jay Perman, Richard Lofgren, et al.
The Science of the Total Environment|September 2, 2024
Potential for large losses of carbon from non-native conifer plantations on deep peat over decadal timescalesThomas J Sloan, Joshua Ratcliffe, Russell Anderson, et al.
Journal of the Royal Society, Interface|June 29, 2021
Timing HIV infection with a simple and accurate population viral dynamics modelDaniel B Reeves, Morgane Rolland, Bethany L Dearlove, et al.
The Journal of Infectious Diseases|May 8, 2012
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)Ann Duerr, Yunda Huang, Susan Buchbinder, et al.
Bioorganic & Medicinal Chemistry Letters|March 24, 2010
Synthesis and bioluminescence-inducing properties of autoinducer (S)-4,5-dihydroxypentane-2,3-dione and its enantiomerManikandan Kadirvel, William T Stimpson, Souad Moumene-Afifi, et al.
Journal of Virology|July 30, 2005
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccinesJohn R Mascola, Patricia D'Souza, Peter Gilbert, et al.
Human Vaccines & Immunotherapeutics|March 10, 2015
Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infectionSandhya Vasan, Supachai Rerks-Ngarm, Peter Gilbert, et al.
The Journal of Infectious Diseases|December 4, 2012
Reply to Richie and VillasanteAnn Duerr, Yunda Huang, Susan Buchbinder, et al.
Science Translational Medicine|April 22, 2011
HIV-1 vaccines and adaptive trial designsLawrence Corey, Gary J Nabel, Carl Dieffenbach, et al.
Plos One|September 7, 2012
MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral loadHolly Janes, Nicole Frahm, Allan DeCamp, et al.
Pageof 10